---
title: "Singh 2024 — Bioinformatics-Driven Insights for Erectile Dysfunction Treatment"
type: source
created: 2026-04-19
updated: 2026-04-19
authors: [Vinay Kumar Singh]
corresponding_author: "Dr. Vinay Kumar Singh"
corresponding_email: ""
institution: "Centre for Bioinformatics, School of Biotechnology, Institute of Science, Banaras Hindu University, Varanasi, Uttar Pradesh, India"
orcid: ""
year: 2024
journal: "International Journal of Advanced Research in Education and Technology (IJARETY)"
doi: "10.15680/IJARETY.2024.1105015"
pmid: ""
evidence_level: computational-prediction
sample_size: "N/A (review with structural analysis)"
tags: [erectile-dysfunction, bioinformatics, PDE5-inhibitors, drug-discovery, microbiome, proteomics, genomics, structural-biology]
library_category: drug-repurposing
platform: both
condition: "erectile dysfunction"
karen_brain_primitives: [4, 5]
metals_discussed: []
taxa_discussed: []
key_findings:
  - "Structural analysis of PDE5-avanafil complex (PDB 6L6E) reveals key hydrogen bonds with Tyr612, Gln817, His613 and hydrophobic interactions conferring high selectivity"
  - "STITCH network analysis maps 10 ED compounds across PDE inhibition, dopaminergic, and adrenergic pathways"
  - "Gut microbiome is identified as a promising emerging area linking microbial ecology to vascular and erectile function"
keystone: false
stub: false
---

## Key Findings

- **Structural analysis of PDE5-avanafil binding** (PDB ID: 6L6E, resolved at 2.0 A) identifies key residues — GLN775 and GLN817 form conventional hydrogen bonds, ALA779 contributes carbon hydrogen bonds, and multiple hydrophobic residues (VAL782, ALA767, ALA783, ILE768, ILE813, LEU804, ILE729, ILE824) stabilize avanafil in the catalytic pocket. Pi-stacking with PHE786 and PHE820 further secures the aromatic rings (computational-prediction).
- **STITCH network visualization** maps interactions among 10 ED compounds (papaverine, sildenafil, alprostadil, apomorphine, yohimbine, vardenafil, tadalafil, moxisylyte, avanafil, udenafil) across three mechanistic pathways: PDE inhibition/vasodilation, dopaminergic stimulation, and adrenergic antagonism. PDE5A is the common molecular target for the majority (computational-prediction).
- **NOS3 gene variants** affecting nitric oxide production are highlighted as a genomic contributor to ED, with proteomic studies revealing associated biomarkers for diagnosis and therapeutic targeting (computational-prediction).
- **Gut microbiome** is identified as an emerging research frontier in ED, with bioinformatics tools enabling analysis of microbial contributions to vascular and erectile function — though no specific taxa or mechanistic data are presented in this paper (computational-prediction).

## Methods

This is a narrative review combining structural biology analysis with network pharmacology. The primary computational method involves analysis of the human PDE5A catalytic core crystal structure bound to avanafil (PDB ID: 6L6E). Drug-target interaction networks were generated using the STITCH database. Pathway analysis references KEGG and Reactome for nitric oxide (NO) and cGMP signaling pathways. No original experimental data were generated; all findings are derived from existing databases and published literature.

## Detailed Summary

**Erectile dysfunction** affects millions of men globally and involves complex vascular, neurogenic, and psychological factors. This paper reviews how bioinformatics approaches — genomics, proteomics, structural biology, network pharmacology, machine learning, and microbiome analysis — can advance understanding and treatment of ED.

**Structural biology.** The crystal structure of human PDE5A complexed with avanafil (PDB 6L6E) was analyzed in detail. The binding site involves a network of hydrogen bonds (GLN775, GLN817, ALA779), hydrophobic contacts (VAL782, ALA767, ALA783, ILE768, ILE813, LEU804, ILE729, ILE824), and aromatic pi-stacking interactions (PHE786, PHE820). These interactions explain avanafil's high selectivity for PDE5 over other phosphodiesterase isoforms.

**Network pharmacology.** A STITCH network analysis of 10 ED compounds reveals three major mechanistic classes:
1. **PDE inhibitors** (sildenafil, tadalafil, vardenafil, avanafil, udenafil, papaverine) — inhibit cGMP or cAMP breakdown, promoting smooth muscle relaxation and vasodilation
2. **Dopaminergic agonists** (apomorphine) — act centrally via DRD1, DRD2, DRD4
3. **Adrenergic antagonists** (yohimbine, moxisylyte) — block alpha-adrenergic receptors to increase blood flow

Alprostadil (prostaglandin E1 analogue) operates via a distinct cAMP-mediated mechanism.

**Genomics and proteomics.** Variations in the **NOS3 gene** (endothelial nitric oxide synthase) are linked to ED through impaired NO production. Proteomic studies have identified potential biomarkers for ED diagnosis and treatment stratification.

**Pathway analysis.** KEGG and Reactome databases map the nitric oxide (NO) signaling pathway and cGMP cascade critical for erectile function.

**Machine learning.** Predictive models analyzing genetic and lifestyle data show potential for identifying high-risk patients and tailoring treatment.

**Microbiome.** The gut microbiome is briefly noted as an emerging research area implicated in systemic conditions including ED, with bioinformatics tools enabling detailed analysis of microbial contributions to vascular function. No specific taxa, metal dependencies, or mechanistic details are provided.

**Compound table.** The paper catalogues 10 ED treatment compounds with PubChem CID numbers and molecular weights, ranging from apomorphine (267.32 g/mol) to udenafil (516.7 g/mol).

## Relevance to WikiBiome

- The microbiome connection to ED is acknowledged but undeveloped in this paper — it serves primarily as a pointer to the emerging gut-vascular axis literature rather than providing substantive data. WikiBiome's [[erectile-dysfunction]] entity page and related microbiome content are better served by dedicated microbiome-ED studies.
- The NO/cGMP signaling pathway content could inform the [[nitric-oxide]] concept page and the connection between vascular function and microbial ecology.
- The pharmacological classification of ED drugs provides useful background context for understanding how conventional treatments interact with the biological systems WikiBiome covers.

## Relevance to Cureva

- The drug interaction network (STITCH analysis) provides a pharmacological map that could complement Cureva's intervention reasoning — understanding which molecular targets conventional ED drugs act on helps identify where microbiome-targeted interventions might synergize or conflict.
- The structural analysis of PDE5 inhibitor binding is relevant to drug repurposing considerations in the [[erectile-dysfunction-signature]].
- The mention of NOS3 variants could inform personalized intervention strategies — patients with specific NOS3 polymorphisms may respond differently to both conventional and microbiome-targeted interventions.

## Contradictions / Tensions

- This paper focuses almost entirely on pharmacological and computational approaches with minimal microbiome content. The microbiome section is a single paragraph acknowledging the field exists without contributing data or mechanistic insight. This contrasts with the growing body of literature linking specific gut taxa to ED via TMAO, bile acid, and NO pathways.
- The paper is published in a general education/technology journal rather than a specialized biomedical journal, which limits its weight as a clinical reference.

## Open Questions

- Which specific gut taxa influence erectile function through vascular pathways, and do any of them depend on metals covered in the WikiBiome knowledge graph?
- Could PDE5 inhibitor metabolism be affected by gut microbial drug metabolism (pharmacomicrobiomics)?
- Do NOS3 gene variants correlate with specific microbiome compositions that independently affect NO availability?
